CV Therapeutics Overview

  • Founded

  • 1990

Founded
  • Status

  • Acquired/​Merged

  • Employees

  • 550

Employees
  • Latest Deal Type

  • M&A

  • Latest Deal Amount

  • $1.4B

CV Therapeutics General Information

Description

Developer and marketer of novel, small molecule drugs for the treatment of cardiovascular diseases. The company's major products were Ranexa (ranolazine extended-release tablets) and Lexiscan (regadenoson).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Gilead Sciences
Primary Office
  • 3172 Porter Dr
  • Palo Alto, CA 94304
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CV Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 17-Apr-2009 $1.4B 00000 00.00 Completed Generating Revenue
8. PIPE 16-Apr-2008 00000 00000 Completed Generating Revenue
7. PIPE 18-Apr-2006 00000 00000 Completed Generating Revenue
6. PIPE 01-Aug-2000 00000 00000 Completed Generating Revenue
5. IPO 06-Oct-1999 0000 00000 Completed Generating Revenue
4. Later Stage VC (Series G) 01-May-1996 000.00 000.00 Completed Generating Revenue
3. Later Stage VC (Series E) 01-Nov-1995 00.000 000.00 Completed Generating Revenue
2. Later Stage VC (Series D) 01-Apr-1994 $16.5M $23.4M Completed Generating Revenue
1. Later Stage VC (Series C) 01-Jul-1993 $6.88M $6.88M Completed Generating Revenue
To view CV Therapeutics’s complete valuation and funding history, request access »

CV Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CV Therapeutics Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Acqua Wellington PE/Buyout Minority 000 0000 000000 0
Alloy Ventures Venture Capital Minority 000 0000 000000 0
Asset Management Ventures Venture Capital Minority 000 0000 000000 0
Axon Capital Hedge Fund Minority 000 0000 000000 0
Azimuth Opportunity Investment Bank Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

Ready to get started?

Request a free trial